Neoadjuvant and adjuvant capmatinib in resectable non-small cell lung cancer with MET exon 14 skipping mutation or high MET amplification: GEOMETRY-N trial

Category Primary study
JournalCancer Research
Year 2022
This article has no abstract
Epistemonikos ID: def26df432adeef5467250581e2c0d95750a060b
First added on: Feb 14, 2025